胱抑素 9 和 C 联合调节与炎症相关的血清生物标志物，并提供针对多药耐药的预防和长期保护。
Combination of Cystatins 9 and C Modulates Serum Biomarkers Associated with Inflammation and Provides Prophylactic as Well as Long-Term Protection against Multidrug-Resistant .
机构信息
Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
The South Texas Center for Emerging Infectious Diseases, Department of Biology, University of Texas at San Antonio, San Antonio, Texas, USA.
出版信息
Antimicrob Agents Chemother. 2019 Apr 25;63(5). doi: 10.1128/AAC.02519-18. Print 2019 May.
We have identified recombinant human cystatins 9 (rCST9) and C (rCSTC) as a combination immunotherapeutic treatment against multidrug-resistant (MDR) New Delhi metallo-β-lactamase-1 (NDM-1)-producing We evaluated the lasting protection of rCST9/rCSTC treatment against MDR NDM-1 pneumonia. Results showed that rCST9/rCSTC treatment modulated endogenous serum biomarkers, cystatins 9 and C and amyloid A, associated with poor patient outcomes and provided prophylactic and long-term protection in a murine model of pneumonia.
我们已鉴定出重组人半胱氨酸蛋白酶抑制剂 9（rCST9）和 C（rCSTC）作为一种联合免疫治疗方法，用于治疗多药耐药（MDR）新德里金属β-内酰胺酶-1（NDM-1）产生的肺炎。我们评估了 rCST9/rCSTC 治疗对 MDR NDM-1 肺炎的持久保护作用。结果表明，rCST9/rCSTC 治疗可调节与患者预后不良相关的内源性血清生物标志物胱抑素 9 和 C 以及淀粉样蛋白 A，并在肺炎的小鼠模型中提供预防和长期保护。
Zotero 插件